(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 19 May 2005 (19.05.2005)

PCT

(10) International Publication Number WO 2005/044787 A1

- (51) International Patent Classification⁷: C07C 275/32, 279/18, 217/60, 233/25, 235/42, 255/54, C07D 213/82, 307/68, C07C 311/08, 311/29, 307/10, 317/22, A61K 31/135, 31/165, 31/18
- (21) International Application Number:

PCT/EP2004/011963

- (22) International Filing Date: 21 October 2004 (21.10.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0324886.1

24 October 2003 (24.10.2003) GF

- (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): BIGGADIKE, Keith [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).
- (74) Agent: FLORENCE, Julia Anne; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Middlesex Greater London TW8 9GS (GB).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHENETANOLAMINE DERIVATIVES

$$Ar^{1} - CHCH_{2}NHCR^{4}R^{5}(CH_{2})_{k} - (CH_{2})_{n}O(CH_{2})_{m}Z-(CH_{2})_{p}(CR^{8}R^{5})_{t} - (I)$$

(57) Abstract: Compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example asthma or chronic obstructive pulmonary disease (COPD).